Given our preclinical and clinical data to date, anti-ErbB3 therapies like seribantumab may have the potential to significantly enhance clinical activity of standard of care therapies by combating persistent drug-tolerant cancer cells via the inhibition of the HRG-ErbB3 pathway. This evidence concerns the gene ERBB3 and cancer.